Discover why Altimmune (ALT) and Viking Therapeutics (VKTX) are top picks for high-risk investors. Click here to read my most ...

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's ...

Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Altimmune, Inc. (NASDAQ:ALT) was one of ...

Altimmune stock rose on Tuesday without news, possibly due to high short interest. Its new trial for Alcohol Use Disorder and ...

Altimmune continues to focus on developing pemvidutide, particularly targeting NASH, a market with significant unmet medical needs. The company anticipates a transformative year in 2025, with key ...

GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...

About Altimmune Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company's lead ...